Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort studyN. El Ouardi, A. Bezza, A. El Maghraoui et al.|Rheumatology International|2022Cited by 11
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registryS. Fellous, F. Allali, Hanan Rkain et al.|Rheumatology International|2021Cited by 10
Therapeutic Maintenance Level of Methotrexate in Rheumatoid Arthritis: A RBSMR StudyLamia Oulkadi, R. Bahiri, Bouchra Amine et al.|Mediterranean Journal of Rheumatology|2022Cited by 5
Active Tuberculosis Infection in Moroccan Patients with Rheumatic Diseases under Biologic TherapyIlham Aachari, F. Allali, Latifa Tahiri et al.|International Journal of Mycobacteriology|2022Cited by 4
Utilisation des AINS et des antalgiques chez les patients ayant une spondyloarthrite sous biothérapie. Données du registre de biothérapie de la Société Marocaine de rhumatologie (RBSMR)Anass Kherrab, R. Niamane, Hanane Chitachen et al.|Revue du Rhumatisme|2020Cited by 2